Nelson R
Surgery, University of Illinois, 1740 West Taylor, Room 2204 m/c 957, Chicago, Illinois 60612, USA.
Cochrane Database Syst Rev. 2003(4):CD003431. doi: 10.1002/14651858.CD003431.
Because of the disability associated with surgery for anal fissure and the risk of incontinence, medical alternatives for surgery have been sought. Most recently, pharmacologic methods that relax the anal smooth muscle, to accomplish reversibly what occurs in surgery, have been used to obtain fissure healing.
To assess the efficacy and morbidity of various medical therapies for anal fissure.
Search terms include "anal fissure randomized".
Studies in which participants were randomized to a non-surgical therapy for anal fissure. Comparison groups may include an operative procedure, an alternate medical therapy or placebo. Chronic fissure, acute fissure and fissure in children are included in the review. Atypical fissures associated with inflammatory bowel disease or cancer or anal infection are excluded.
Data were abstracted from published reports and meeting abstracts, assessing method of randomization, blinding, "intention to treat" and drop-outs, therapies, supportive measures (applied to both groups), dosing and frequency and cross-overs. Dichotomous outcome measures included Non-healing of the fissure (a combination of persistence and recurrence), and Adverse events (including incontinence, headache, infection, anaphylaxis). Continuous outcome measures included measures of pain relief and anorectal manometry.
21 different comparisons of the ability of medical therapies to heal anal fissure have been reported in 31 RCTs. Nine agents were used (nitroglycerin ointment (GTN), isosorbide dinitrate, Botulinum toxin (Botox), diltiazem, nifedipine (Calcium channel blockers or Cachablos), hydrocortisone, lignocaine, bran, placebo) as well as anal dilators and surgical sphincterotomy. When two studies are excluded from analysis due to quality concerns, the significance disappears in the three main analyses: GTN vs. placebo group (0.78; 0.56-1.08), in children (0.96; 0.48-1.92) and adults (0.73; 0.50-1.07). That is, GTN was, in this modified analysis, not significantly better than placebo in curing anal fissure. Cachablos were not tested against placebo, but in a comparison to GTN, Cachablo was equivalent in its ability to cure fissure (odds ratio 0.66; 0.22-2.01). Botox, in a meta-analysis of two studies compared to placebo, showed no significant advantage in efficacy (0.75; 0.32-1.77), and in a comparison to GTN analyzing two studies, was also not significantly better than GTN (0.48; 0.21-1.10).
REVIEWER'S CONCLUSIONS: Medical therapy for chronic anal fissure, acute fissure and fissure in children may be applied with a chance of cure that is only marginally better than placebo, and, for chronic fissure in adults, far less effective than surgery.
由于肛裂手术会导致残疾以及存在失禁风险,人们一直在寻求手术的替代医疗方法。最近,已采用可使肛门平滑肌松弛的药理学方法,以可逆方式实现手术所达成的效果,从而促进肛裂愈合。
评估各种肛裂药物治疗方法的疗效和发病率。
检索词包括“肛裂随机对照试验”。
将参与者随机分配至肛裂非手术治疗组的研究。比较组可包括手术操作、替代药物治疗或安慰剂。本综述纳入慢性肛裂、急性肛裂及儿童肛裂。排除与炎症性肠病、癌症或肛门感染相关的非典型肛裂。
数据取自已发表报告和会议摘要,评估随机化方法、盲法、“意向性分析”及失访情况、治疗方法、支持性措施(两组均采用)、给药剂量和频率以及交叉情况。二分法结局指标包括肛裂未愈合(持续性和复发性的综合情况)及不良事件(包括失禁、头痛、感染、过敏反应)。连续性结局指标包括疼痛缓解程度和肛门直肠测压。
31项随机对照试验报告了21种不同药物治疗肛裂能力的比较。使用了9种药物(硝酸甘油软膏(GTN)、二硝酸异山梨酯、肉毒杆菌毒素(肉毒素)、地尔硫䓬、硝苯地平(钙通道阻滞剂或卡查布罗斯)、氢化可的松、利多卡因、麸皮、安慰剂)以及肛门扩张器和手术括约肌切开术。由于质量问题将两项研究排除在分析之外后,在三项主要分析中显著性消失:GTN与安慰剂组比较(0.78;0.56 - 1.08),儿童组(0.96;0.48 - 1.9)及成人组(0.73;0.50 - 1.07)。也就是说,在这项修正分析中,GTN在治愈肛裂方面并不显著优于安慰剂。卡查布罗斯未与安慰剂进行对照试验,但与GTN比较时,其治愈肛裂的能力相当(比值比0.66;可信区间0.22 - 2.01)。在两项研究与安慰剂比较的荟萃分析中,肉毒素在疗效方面无显著优势(0.7;0.32 -),在两项研究与GTN比较时,也不比GTN显著更好(0.48;0.21 - 1.10)。
慢性肛裂、急性肛裂及儿童肛裂的药物治疗治愈几率仅略高于安慰剂,而对于成人慢性肛裂,其疗效远低于手术治疗。